Unichem Laboratories receives USFDA approval to market generic labetalol hydrochloride tablets
Unichem Laboratories Ltd announced that it has received approval from the US Food and Drug Administration to market its generic version of labetalol hydrochloride tablets, which are used to treat high blood pressure.
Pharma industry targets $400 billion in sales by 2047 following 100-year road map
Over 90% of the domestic drug market in 2022—which has grown to be worth Rs 1.67 trillion—was dominated by locally produced medications. The industry is now talking about breaking into the top five by 2047.
Snapshot of Worm at core of Pharma Apple at Krebs Biochemicals
Corporate mismanagement, alleged attempts to influence a judge, and illegal manufacturing of life-saving drugs – a publicly traded Andhra Pradesh firm has become the epicentre of the many ills that continue to plague the Indian pharmaceutical sector.
CAG report highlights lapses in CGHS drug procurement and supply chain
The Comptroller and Auditor General of India highlighted several lapses in the procurement and supply chain of drugs under the Central Government Health Scheme in its audit report tabled, which resulted in a drug shortage at wellness centres.
Natco Pharma's first-quarter net profit more than doubled to Rs 320.4 crore
Revenue from the pharmaceutical segment increased to Rs 883.6 crore, up from 409.7 crore in the first quarter of last year. This included earnings from the settlement of claims received by Natco Pharma (Canada) Inc under a settlement agreement.
Sartorius pay £415 million to acquire Albumedix
Known as a pioneer in recombinant human albumin-based products, Albumedix Ltd. recently disclosed that it has signed a binding agreement to be acquired by Sartorius, a world leader in laboratory and bioprocessing technologies for the biopharmaceutical sector.
Drug combinations by AstraZeneca & Daiichi Sankyo show promising against advanced NSCLC
TROPION-Lung02 phase Ib trial preliminary
results showed promising clinical activity and
a tolerable safety profile in patients with
previously untreated or pretreated, advanced
or metastatic non-small cell lung cancer
(NSCLC) without actionable genomic alterations.
